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OBJECTIVE: To determine the role of peak systolic velocity, end-diastolic velocity and resistance indices of both the
right and left inferior thyroid arteries measured by color-flow Doppler ultrasonography for a differential diagnosis
between gestational transient thyrotoxicosis and Graves’ disease during pregnancy.
METHODS: The right and left inferior thyroid artery-peak systolic velocity, end-diastolic velocity and resistance
indices of 96 patients with thyrotoxicosis (41 with gestational transient thyrotoxicosis, 31 age-matched pregnant
patients with Graves’ disease and 24 age- and sex-matched non-pregnant patients with Graves’ disease) and 25 age-
and sex-matched healthy euthyroid subjects were assessed with color-flow Doppler ultrasonography.
RESULTS: The right and left inferior thyroid artery-peak systolic and end-diastolic velocities in patients with
gestational transient thyrotoxicosis were found to be significantly lower than those of pregnant patients with
Graves’ disease and higher than those of healthy euthyroid subjects. However, the right and left inferior thyroid
artery peak systolic and end-diastolic velocities in pregnant patients with Graves’ disease were significantly lower
than those of non-pregnant patients with Graves’ disease. The right and left inferior thyroid artery peak systolic and
end-diastolic velocities were positively correlated with TSH-receptor antibody levels. We found an overlap between
the inferior thyroid artery-blood flow velocities in a considerable number of patients with gestational transient
thyrotoxicosis and pregnant patients with Graves’ disease.
CONCLUSIONS: This study suggests that the measurement of inferior thyroid artery-blood flow velocities with color-
flow Doppler ultrasonography does not have sufficient sensitivity and specificity to be recommended as an initial
diagnostic test for a differential diagnosis between gestational transient thyrotoxicosis and Graves’ disease during
pregnancy.
KEYWORDS: Gestational transient thyrotoxicosis; Graves’ disease; Inferior thyroid artery; Color-flow Doppler
ultrasonography; Pregnancy.
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INTRODUCTION
Thyrotoxicosis affects up to 0.1% to 0.4% of pregnancies.
Graves’ disease (GD) is the overwhelming autoimmune
cause of thyrotoxicosis during pregnancy. Unless it is
treated, thyrotoxicosis may result in maternal and fetal
complications (1-3). In contrast, gestational transient thyr-
otoxicosis (GTT) is a non-autoimmune cause of thyrotox-
icosis of variable severity that is often associated with
hyperemesis gravidarum (HG) (2-4). GTT is defined as
transient thyrotoxicosis during early pregnancy with a lack
of clinical features of GD, no evidence of hyperthyroidism
before pregnancy and an absence of thyroid autoantibodies
(2). The etiology of GTT is thought to be related to
stimulation of the thyroid gland by human chorionic
gonadotropin (hCG) or related molecular variants (2-6).
Apart from rare cases in which persistent and severe clinical
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symptoms might require treatment with low doses of anti-
thyroid drugs, usually for a short period of time, GTT often
resolves spontaneously before 18 weeks of gestation (1-7).
Other causes of thyrotoxicosis such as toxic multinodular
goiter, single toxic adenoma and different forms of
destructive thyroiditis are rare during pregnancy. Because
nonspecific symptoms of hyperthyroidism may occur
normally in pregnancy, the evaluation of thyrotoxicosis in
a pregnant woman is difficult. In the presence of thyrotox-
icosis with clinical features of GD, the diagnosis is
straightforward. However, the differential diagnosis
between GD and GTT is difficult in the absence of clinical
features of GD. The assessment of TSH-receptor antibody
(TRAb) levels is generally useful when investigating
thyrotoxicosis of uncertain etiology, including thyrotoxico-
sis associated with HG (8). Although the new generation of
TSH-receptor antibody (TRAb) assays is highly sensitive
and specific for discriminating GD from various causes of
thyrotoxicosis (9), these assays are not widely available, and
cost remains an important factor when considering their use
in routine clinical practice. Recently, the measurement of the
peak systolic velocity (PSV) of the inferior thyroid artery
(ITA) with color-flow Doppler ultrasonography (CFDUSG)
was suggested as a sensitive diagnostic tool for the
differential diagnosis of thyrotoxicosis (10,11). Previously,
Kumar et al. indicated the utility of CFDUSG for the
differential diagnosis of thyrotoxicosis during pregnancy
(12). However, because of the small number of patients
included, Kumar et al. were not able to determine the exact
role of CFDUSG for a differential diagnosis between GTT
and GD. Therefore, we conducted the present study to
evaluate the role of PSV, end-diastolic velocity (EDV) and
resistance indices (RIs) of the right and left ITA, measured
with CFDUSG, for a differential diagnosis between GTT and
GD during pregnancy.
PATIENTS AND METHODS
Patients
Seventy-eight pregnant women in their first trimester of
pregnancy (between 8-12 weeks gestation) who were
referred to our center for evaluation of thyrotoxicosis, 24
age-matched non-pregnant patients with GD and 25 age-
and sex-matched healthy euthyroid subjects were enrolled
in this study. All of the cases were newly diagnosed and had
not received antithyroid therapy before inclusion in the
study. A detailed history was taken, and all patients with
thyrotoxicosis were examined physically for clinical features
of GD (ophthalmopathy, a significant goiter, pretibial
myxedema and nail changes). Patients with a history of
previous thyroid surgery, radioactive iodine ablation
therapy and radiation exposure to the neck; patients with
single or multinodular goiter on gray-scale ultrasonography
(USG); patients with destructive thyroiditis; and patients
under treatment with thionamides or L-thyroxine were
excluded from the study. Accordingly, six pregnant patients
with thyrotoxicosis (two with multiple nodules and one
with a single nodule on USG, one with factitious thyrotox-
icosis, one with painless thyroiditis and one with a previous
history of radiation therapy to the neck for the treatment of
childhood lymphoma) were excluded from the study.
Eventually, 72 pregnant patients with thyrotoxicosis (41
with GTT and 31 with GD) were found to be eligible for the
study. GTT was defined as suppressed TSH and high free
thyroid hormone levels presenting within the first trimester
of pregnancy and associated with HG, but self-limiting on
follow-up; absence of clinical findings of GD; a normal
TRAb level; and absence of a history of hyperthyroidism
before pregnancy (13). GD in pregnant patients was defined
based on clinical findings, high TRAb and free thyroid
hormone levels, decreased TSH levels and presence of a
history of hyperthyroidism before pregnancy. GD in non-
pregnant patients was defined based on the clinical
findings, decreased TSH level, high free thyroid hormone
and TRAb levels and high uptake values for 99mTc-
pertechnetate. Destructive thyroiditis in pregnant women
was defined as the presence of thyrotoxicosis lasting for
fewer than three months and/or later development of
transient hypothyroidism associated with a positive result
for thyroid peroxidase and/or thyroglobulin antibodies,
normal TRAb levels, decreased echogenicity and hetero-
geneous appearance of the thyroid parenchyma on USG and
low uptake values for 99mTc-pertechnetate in non-pregnant
patients with thyrotoxicosis. HG was defined as electrolyte
disturbances, ketosis and weight loss of .%5 of the non-
pregnant weight (13).
Hormone assays
Serum samples to determine TSH, fT3 and fT4 levels for
all subjects; TRAb level in all patients with thyrotoxicosis;
and b hCG level in all pregnant patients were collected after
an overnight fast and sent immediately for laboratory
assessment on the day of ultrasonography examination.
Serum TSH, fT3, fT4 and b HCG levels were assessed
using a direct chemiluminescence immunoassay (Siemens,
ADVIA Centaur XP Immunoassay System, Tarrytown, NY,
USA). Serum TRAb levels were assessed with TRAb-Fast-
ELISA (Euroimmun AG Seekamp 31, D-23560 Lu¨beck.
Germany) (14).
Doppler ultrasonography
All thyroid ultrasound examinations were performed by
the same radiologist (A.O.), who was blinded to the clinical
status of the subjects. A color Doppler ultrasound scanner
(Toshiba, Aplio XV, Tokyo, Japan) equipped with a 7-
14 MHz broadband linear array transducer was used. The
studies of the right and left ITAs were performed with
transverse scanning, in which the vessels crossed the
common carotid arteries posteriorly, or with longitudinal
scanning of the ascending parts of the arteries, in which the
vessels lay parallel to the common carotid arteries. The
angle correction cursor was parallel to the direction of flow,
and the Doppler angle was kept at or below 60 .˚ The PSV,
EDV and RI values were obtained from the right and left
ITA.
Maternal thyroid function was monitored with respect to
fT3, fT4 and TSH levels at monthly intervals. All pregnant
patients diagnosed with GTT were followed up until the
normalization of the TSH level without treatment with
antithyroid drugs. Antithyroid therapy with propiltiouracil
(PTU) was administered after the assessment of thyroid
blood flows to all pregnant patients diagnosed with GD,
and the patients were followed up until delivery. The aim of
the treatment was to maintain the FT3/FT4 in the upper
quartile of the normal, non-pregnant range. Non-pregnant
patients with GD were treated appropriately. Informed
consent was obtained from all participants, and the study
was approved by the local ethics committee.
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Statistical analysis
Data were analyzed using SPSS version 12.0.0 for
Windows (SPSS Inc., Chicago, IL). Scale variables are
presented as the mean ¡ standard deviation (mean ¡
SD). Categorical data were evaluated using Chi-square
analysis or with Pearson’s correlation and Fisher’s exact
tests as appropriate. Student’s t-test was used for a
comparison of parametric quantitative data. A one-way
analysis of variance (ANOVA) was performed to compare
quantitative variables within different groups followed by
post-hoc analyses for multiple comparisons (Tamhane’s
test). A canonical correlation analysis was used to determine
the correlation between the ITA flow velocity and the TRAb
level. Patients with GTT were tested to determine a
diagnostic cutoff for the right and left ITA-PSV and
EDV using receiver-operating-characteristic (ROC) analysis.
p,0.05 was considered to be statistically significant.
RESULTS
The demographic and laboratory features of the study
participants are summarized in Table 1. In the present
study, the right and left ITA-PSV and EDV in patients with
GTT were lower than those of pregnant patients with GD
(p,0.001) and higher than those of euthyroid subjects
(p,0.001). However, the right and left ITA-PSV and EDV
in pregnant patients with GD were lower than those of non-
pregnant patients with GD (p,0.001). The right and left
ITA-RI were not different among the four groups of study
participants (p.0.05). The mean, minimum and maximum
ITA-flow velocities of all groups of study participants are
shown in Table 2.
In the current study, 30 (97%) of 31 pregnant patients with
GD and 23 (96%) of 24 non-pregnant patients with GD had
high TRAb levels. The TRAb levels were also significantly
different among the three groups of patients with thyrotox-
icosis (p,0.001 for all groups with thyrotoxicosis). The
canonical r coefficient of the correlation demonstrated a
positive correlation of the right and left ITA-PSV and EDV
with the TRAb levels (r = 0.515, p= 0.440 for the right ITA
PSV, r = 0.463, p = 0.461 for the left ITA-PSV, r = 0.615,
p= 0.356 for the right ITA-EDV and r = 0.526, p= 0.382 for
the left ITA-EDV, respectively). However, of the patients
with GTT, nine (22%) had right ITA-PSV, 13 (31.7%) had left
ITA-PSV, 12 (29.3%) had right ITA-EDV, and 13 (31.7%) had
left ITA-EDV above the cutoff values. Similarly, of the
pregnant patients with GD, seven (22.6%) had right ITA-
PSV, eight (25.8%) had left ITA-PSV, eight (25.8%) had right
ITA-EDV, and eight (25.8%) had left ITA-EDV below the
cutoff values. Hence, an overlap was found among ITA
blood flow velocities in a considerable number of patients
with GTT and pregnant patients with GD. The most
appropriate cutoff values for the right and left ITA-PSV
and EDV for differentiating GTT from GD during preg-
nancy are presented in Table 3.
The TSH, fT3 and fT4 levels returned to normal pre-
pregnancy levels before the 20th week of pregnancy in
patients with GTT. However, despite treatment with
different doses of PTU, the TSH levels in the 20th week of
pregnancy were significantly lower in pregnant patients
with GD than in those with GTT (p,0.001). The fT3 and fT4
levels in the 20th week of pregnancy were not different
between patients with GTT and pregnant patients with GD
(p.0.05) (Table 1). Because the thyroid function returned to
normal before the 20th week of pregnancy in patients with
GTT, the thyroid function was only followed in pregnant
patients with GD beyond the 20th week of pregnancy. The
TSH levels also remained reduced after the 30th week of
pregnancy in the majority of pregnant patients with GD,
irrespective of treatment with PTU.
Table 1 - Demographic information and laboratory values of the study participants.
patients
with GTT
pregnant patients
with GD
non-pregnant
patients with GD
healthy euthyroid
subjects p-value
(n = 41) (n = 31) (n = 24) (n = 25)
Age (years) 29.1¡4.8 29.1¡5.12 29.1¡3.5 30.8¡7.1 0.29
Hyperemesis gravidarum (%) 73.2 19.4 - - ,0.001
Multiple pregnancy (%) 7.3 9.7 - - 0.52
TSH (0.55-4.78 mIU/ml)d,e 0.03¡ 0.03 0.03¡0.07 0.007¡0.005 1.62¡0.85 -
fT3 (2.3-4.2 pg/ml)b,c 3.94¡0.95 5.57¡2.21 25.86¡40.97 3.05¡0.388 -
fT4 (0.76-1.4 ng/dl)f 1.73¡ 0.36 2.11¡1.25 5.86¡12.7 1.03¡0.13 -
TRAb (,1 IU/L)a 0.28¡0.22 3.47¡1.43 14.09¡11.71 - -
bhCG (mIU/ml) 111965¡52688 103043¡65998 - - 0.79
20 weeks TSH level 1.05¡0.5 0.34¡0.43 - - ,0.001
20 weeks fT3 level 2.73¡0.29 2.95¡0.45 - - 0.71
20 weeks fT4 level 0.92¡0.09 0.95¡0.13 - - 0.058
34 weeks TSH level - 0.38¡0.45 - -
34 weeks fT3 level - 2.91¡0.44 - -
34 weeks fT4 level - 0.99¡0.15 - -
ap,0.001 when GTT was compared with pregnant patients with GD, when pregnant patients with GD were compared with non-pregnant patients with
GD and when GTT was compared with non-pregnant patients with GD.
bp= 0.003 when GTT was compared with pregnant patients with GD.
cp.0.05 when GTT and pregnant patients with GD were compared with non-pregnant patients with GD.
dp,0.001 when GTT was compared with non-pregnant patients with GD.
ep.0.05 when GTT was compared with pregnant patients with GD and when pregnant patients were compared with non-pregnant patients with GD.
fp.0.05 when GTT was compared with pregnant patients with GD, when pregnant patients were compared with non-pregnant patients with GD and
when GTT was compared with non-pregnant patients with GD.
GTT: gestational transient thyrotoxicosis, GD: Graves’ disease, TSH: thyroid-stimulating hormone, fT3: free triiodothyronine, fT4: free thyroxine, TRAb:
TSH-receptor antibody, b hCG: b human chorionic gonadotropin; values in parentheses indicate normal laboratory reference ranges.
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DISCUSSION
Determination of the etiology of thyrotoxicosis during
pregnancy is crucial for providing the patient with an
appropriate treatment plan. The measurement of ITA-PSV
using CFDUSG has proven to be highly sensitive and
specific in identifying patients with GD (11), but its
capability to discriminate GTT from GD during pregnancy
is not well known. According to our findings, the mean
right and left ITA-PSV and EDV in patients with GTT was
significantly lower than that in pregnant and non-pregnant
patients with GD and significantly higher than that in
healthy euthyroid subjects, which is a result that has not
been found before. This increase in the mean ITA-PSV and
EDV in GTT is most likely a result of the stimulation of the
thyroid gland by hCG or molecular variants of hCG with
higher thyrotrophic activity.
In the present study, the right and left ITA-PSV and EDV
were found to be significantly lower in pregnant than in
non-pregnant patients with GD. GD is an autoimmune
disease, and the TRAb level plays a central role in the
pathogenesis of GD (15). In clinical practice, GD can be
diagnosed based upon the clinical presentation of the
patients; however, TRAb level is useful for establishing a
diagnosis in uncertain clinical situations, including the
differential diagnosis between GTT and GD during preg-
nancy (16). In this study, the TRAb level was normal in all
patients with GTT, and it was higher than normal in 97%
and 96% of pregnant and non-pregnant patients with GD,
respectively. This result was consistent with previous
reports (17,18). However, similar to ITA-PSV and EDV, the
TRAb level among GD patients was significantly lower in
pregnant patients than in non-pregnant patients.
Pregnancy has a profound effect on the immune system
and, as in other autoimmune diseases, the autoantibody titers
decrease in autoimmune thyroid diseases during pregnancy
(19,20). Although still not fully understood, it is thought that
these changes in the immune system occur to protect the fetal
allograft during pregnancy (19,20). Although no other studies
have compared TRAb levels between pregnant and non-
pregnant patients with newly diagnosed GD, the lower
serum TRAb levels observed in pregnant compared with
non-pregnant patients in this study are most likely related to
the immunosuppressive effect of pregnancy.
In the current study, we also found a positive correlation
between ITA blood flow velocities and TRAb levels. Ueda
et al. previously found that the serum TRAb level was
significantly and positively correlated with ITA PSV in
patients whose GD had relapsed (21). Baldini et al. also
found an association of increased ITA-PSV and high levels
of TRAb in the relapsing form of GD and suggested that
thyroid hypervascularization was most likely related to the
activity of the underlying autoimmune processes (22). As
demonstrated in our study, among GD patients, the lower
ITA blood flow velocities in pregnant compared with non-
pregnant patients may be related to the lower TRAb levels
seen in pregnant patients with GD. Presumably, as a result
of the lower TRAb levels seen in pregnant patients with GD
as well as the stimulation of the thyroid gland stimulation
by hCG or its molecular variants in patients with GTT, an
overlap occurred between the ITA blood flow velocities
measured with CFDUSG. Consequently, the diagnostic
value of the ITA blood flow velocity measured with
CFDUSG was not high during pregnancy. These results
also suggest that high ITA blood flow velocities are neither
pathognomonic nor specific for GD and can be seen in GTT.
Table 2 - The right and left ITA blood flow velocities of the study participants.
patients with GTT
pregnant patients
with GD
non-pregnant
patients with GD
healthy euthyroid
subjects
(n = 41) (n = 31) (n = 24) (n = 25)
Right ITA PSV cm/seca 24.3¡7.3 (10.6-42) 37.58¡10.89 (20.9-58.1) 57.03¡25.7 (11.6-129.8) 17.08¡4.83 (9.4-30)
Right ITA EDV cm/seca 10.39¡3.7 (3.1-20) 15.9¡6.2 (7-33.6) 24.03¡11.87 (3.9-53.8) 7.78¡3.07 (4.1-14.4)
Right ITA RIb 0.57¡0.07 (0.45-0.71) 0.57¡0.08 (0.37-0.72) 0.58¡0.07 (0.48-0.79) 0.55¡0.08 (0.43-0.73)
Left ITA PSV cm/seca 24.75¡6.15 (11.4-36.6) 35.19¡11.19 (21-69.7) 59.4¡ 22.77(22.4-112.5) 17.37¡ 4.81 (9-27)
Left ITA EDV cm/seca 11.43¡3.93 (4.7-21.49) 15.8¡5.05 (6.9-26.6) 25.97¡11.80 (7.6-58.2) 8.16¡2.73 (4.4-13.7)
Left ITA RIb 0.54¡0.074 (0.4-0.8) 0.54¡0.08 (0.4-0.7) 0.56¡0.07 (0.4-0.7) 0.53¡0.06 (0.4-0.7)
ap,0.001 when GTT was compared with healthy euthyroid subjects as well as pregnant and non-pregnant patients with GD, when pregnant patients with
GD were compared with non-pregnant patients with GD and when pregnant and non-pregnant patients with GD were compared with healthy euthyroid
subjects.
bp.0.05 when GTT was compared with healthy euthyroid subjects as well as pregnant and non-pregnant patients with GD, when pregnant patients with
GD were compared with non-pregnant patients with GD and when pregnant and non-pregnant patients with GD were compared with healthy euthyroid
subjects.
GTT: gestational transient thyrotoxicosis, ITA: inferior thyroid artery, PSV: peak systolic velocity, EDV: end-diastolic velocity, RI: resistance index, R results
are presented as mean¡SD; values in parentheses indicate the minimum and maximum ranges.
Table 3 - The most appropriate cutoff values for the right and left ITA-blood flow velocities for differentiating GTT from
GD during pregnancy.
Cutoff value AUC Sensitivity/Specificity (%) PPV (%) NPV (%) CI (95%)
Diagnostic
accuracy (%)
Right ITA PSV 29.4 cm/sn 0.844 77.4/78 82.1 72.7 0.756-0.932 77
Right ITA EDV 11.95 cm/sn 0.789 74.2/70.7 78.4 65.7 0.685-0.893 72
Left ITA PSV 26.65 cm/sn 0.778 74.2/68.3 77.8 63.9 0.668-0.887 70
Left ITA EDV 12.7 cm/sn 0.750 74.2/68.3 77.8 63.9 0.637-0.864 70
ITA: inferior thyroid artery, PSV: peak systolic velocity, EDV: end-diastolic velocity, AUC: area under the curve, PPV: positive predictive value, NPV: negative
predictive value, CI: confidence interval.
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The main limitation of this study is that all pregnant
patients with thyrotoxicosis were diagnosed with GTT and
GD based mainly on the TRAb level results. Therefore, it
was difficult to compare the ITA blood flow velocity with
TRAb level for differential diagnoses between GTT and GD.
However, the follow-up data from our study demonstrate
that the TRAb level is better than Doppler ultrasonography
for the differential diagnosis of these two distinct diseases
during pregnancy.
In summary, this study suggests that the measurement of
ITA blood flow velocities with CFDUSG does not provide
sufficient sensitivity and specificity to be recommended as
an initial diagnostic test for differential diagnoses between
GTT and GD during pregnancy. CFDUSG may be used as
an auxiliary diagnostic tool, but the results should be
interpreted with caution and in the context of additional
clinical and laboratory findings.
Conflict of interest: The authors of this study declare that
they have no conflicts of interest.
AUTHOR CONTRIBUTIONS
Zuhur SS contributed to the study design, implementation, data analysis
and preparation of the manuscript. O¨zel A performed the ultrasonographic
examinations and contributed to the study design. Velet S, C¸il E recruited
and screened the patients. Bug˘daci MS, Altuntas Y contributed to the data
analysis and preparation of the manuscript.
REFERENCES
1. Burrow GN. Thyroid function and hyperfunction during gestation.
Endocr Rev. 1993;14:194-202.
2. Goldman AM, Mestman JH. Transient non-autoimmune hyperthyroid-
ism of early pregnancy. J Thyroid Res. 2011; http://dx.doi.org/10.4061/
2011/142413.
3. Mestman JH. Hyperthyroidism in pregnancy. Best Pract Res Clin
Endocrinol Metab. 2004;18:267-88, http://dx.doi.org/10.1016/j.beem.
2004.03.005.
4. Glinoer D. The regulation of thyroid function in pregnancy: pathways of
endocrine adaptation from physiology to pathology. Endocr Rev.
1997;18:404-33, http://dx.doi.org/10.1210/er.18.3.404.
5. Glinoer D, De Nayer P, Robyn C, Lejeune B, Kinthaert J, Meuris S. Serum
levels of intact human chorionic gonadotropin (hCG) and its free alpha
and beta subunits, in relation to maternal thyroid stimulation during
normal pregnancy. J Endocrinol Invest. 1993;16:881-8.
6. Kimura M, Amino N, Tamaki H, Ito E, Mitsuda N, Miyai K, et al.
Gestational thyrotoxicosis and hyperemesis gravidarum: possible role of
hCG with higher stimulating activity. Clin Endocrinol (Oxf). 1993;38:345-
50, http://dx.doi.org/10.1111/j.1365-2265.1993.tb00512.x.
7. Goodwin TM, Montoro M, Mestman JH, Pekary AE, Hershman JM. The
role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis
gravidarum. J Clin Endocrinol Metab. 1992;75:1333-7, http://dx.doi.org/
10.1210/jc.75.5.1333.
8. Matthews DC, Syed AA. The role of TSH receptor antibodies in the
management of Graves’disease. Eur J Intern Med. 2011;22:213-6, http://
dx.doi.org/10.1016/j.ejim.2011.02.006.
9. Yoshimura NJ, Miyazaki N, Ito K, Takeda K, Hiramatsu S, Morita S, et al.
Evaluation of a new rapid and fully automated electrochemilumines-
cence immunoassay for thyrotropin receptor autoantibodies. Thyroid.
2008;18:1157-64, http://dx.doi.org/10.1089/thy.2008.0119.
10. Erdogan MF, Anil C, Cesur M, Baskal N, Erdogan G. Color flow Doppler
sonography for the etiologic diagnosis of hyperthyroidism. Thyroid.
2007;17:223-8, http://dx.doi.org/10.1089/thy.2006.0104.
11. Hari Kumar KV, Pasupuleti V, Jayaraman M, Abhyuday V, Rayudu BR,
Modi KD. Role of thyroid Doppler in differential diagnosis of
thyrotoxicosis. Endocr Pract. 2009;15:6-9.
12. Hari Kumar KV, Vamsikrishna P, Verma A, Muthukrishnan J, Meena U,
Modi KD. Evaluation of thyrotoxicosis during pregnancy with color flow
Doppler sonography. Int J Gynaecol Obstet. 2008;102(2):152-5, http://
dx.doi.org/10.1016/j.ijgo.2008.03.014.
13. Abalovich M, Amino N, Barbour LA, Cobin RH, DeGroot LJ, Glinoer D,
et al. Management of thyroid dysfunction during pregnancy and
postpartum: an Endocrine Society Clinical Practice Guideline. J Clin
Endocrinol Metab. 2007;92:1-47, http://dx.doi.org/10.1210/jc.2007-0141.
14. Liu C, Hermsen D, Domberg J, Graeber C, Hautzel H, Duan Y, et al.
Comparison of M22-based ELISA and human-TSH-receptor-based
luminescence assay for the measurement of thyrotropin receptor
antibodies in patients with thyroid diseases. Horm Metab Res.
2008;40:479-83, http://dx.doi.org/10.1055/s-2008-1077051.
15. McKenna TJ. Graves’ disease. Lancet. 2001;357:1793–6, http://dx.doi.
org/10.1016/S0140-6736(00)04906-0.
16. Davies TF, Roti E, Braverman LE, DeGroot LJ. Thyroid controversy-
stimulating antibodies. J Clin Endocrinol Metab. 1998;83:3777–85, http://
dx.doi.org/10.1210/jc.83.11.3777.
17. Vos XG, Smit N, Endert E, Tijssen JG, Wiersinga WM. Frequency and
characteristics of TBII-seronegative patients in a population with untreated
Graves’ hyperthyroidism: a prospective study. Clin Endocrinol (Oxf).
2008;69:311-7, http://dx.doi.org/10.1111/j.1365-2265.2008.03192.x.
18. Theodoraki A, Jones G, Parker J, Woolman E, Martin N, Perera S, et al.
Performance of a third generation TSH-receptor antibody (TRAb) in a UK
clinic. Clin Endocrinol (Oxf). 2011;75:127-33, http://dx.doi.org/10.1111/
j.1365-2265.2011.04022.x.
19. Lazarus JH. Hyperthyroidism during pregnancy: etiology, diagnosis and
management. Womens Health (Lond Engl). 2005;1:97-104, http://
dx.doi.org/10.2217/17455057.1.1.97.
20. Kamijo K. TSH-receptor antibodies determined by the first, second and
third generation assays and thyroid-stimulating antibody in pregnant
patients with Graves’ disease. Endocr J. 2007;54:619-24, http://
dx.doi.org/10.1507/endocrj.K06-196.
21. Ueda M, Inaba M, Kumeda Y, Nagasaki T, Hiura Y, Tahara H, et al. The
significance of thyroid blood flow at the inferior thyroid artery as a
predictor for early Graves’ disease relapse. Clin Endocrinol (Oxf).
2005;63:657-62, http://dx.doi.org/10.1111/j.1365-2265.2005.02397.x.
22. Baldini M, Castagnone D, Rivolta R, Meroni L, Pappalettera M,
Cantalamessa L. Thyroid vascularization by color doppler ultrasono-
graphy in Graves’ disease. Changes related to different phases and to the
long-term outcome of the disease. Thyroid. 1997;7:823-8, http://
dx.doi.org/10.1089/thy.1997.7.823.
CLINICS 2012;67(2):125-129 Doppler for thyrotoxicosis in pregnancy
Zuhur SS et al.
129
